Sipavibart - AstraZeneca
Alternative Names: AZD-3152; KavigaleLatest Information Update: 21 Aug 2026
At a glance
- Originator RQ Bio
- Developer AstraZeneca; RQ Bio
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Coronavirus spike glycoprotein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 12 Jun 2025 Nova Southeastern University plans a phase II trial for Post acute COVID-19 syndrome in USA (IM) in June 2025 (NCT07021794)
- 22 May 2025 Registered for COVID-2019 infections (In adolescents, In the elderly, Prevention, In adults) in Australia (IM)
- 22 May 2025 Registered for COVID-2019 infections (In adolescents, In the elderly, Prevention, In adults) in Australia (IV)